Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga Earnings

03/24

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.

Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core & Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.

On March 16, Fennec Pharmaceuticals announced a settlement agreement resolving PEDMARK patent litigation.

Fennec Pharmaceuticals shares gained 1.8% to close at $7.45 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $18 on Jan. 9, 2026. This analyst has an accuracy rate of 75%.
HC Wainwright & Co. analyst Raghuram Selvaraju maintained a Neutral rating with a price target of $13 on Aug. 21, 2025. This analyst has an accuracy rate of 66%.
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating and boosted the price target from $13 to $14 on Aug. 15, 2025. This analyst has an accuracy rate of 77%.

Considering buying FENC stock? Here’s what analysts think:

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2621868082"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621868082\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621868082?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 04:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621868082","market":"us","top_or_hot":-1,"title":"Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call","media":"Benzinga Earnings","content":"<html><body><p><strong>Fennec Pharmaceuticals Inc</strong>. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.</p>\n<p>Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core &amp; Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.</p>\n<p>On March 16, Fennec Pharmaceuticals announced a settlement agreement resolving PEDMARK patent litigation.</p>\n<p>Fennec Pharmaceuticals shares gained 1.8% to close at $7.45 on Monday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $18 on Jan. 9, 2026. This analyst has an accuracy rate of 75%.</li>\n<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Neutral rating with a price target of $13 on Aug. 21, 2025. This analyst has an accuracy rate of 66%.</li>\n<li>Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating and boosted the price target from $13 to $14 on Aug. 15, 2025. This analyst has an accuracy rate of 77%.</li>\n</ul>\n<p>Considering buying FENC stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"531\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-1024x531.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498.png 1240w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-03-24 04:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Fennec Pharmaceuticals Inc</strong>. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.</p>\n<p>Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core &amp; Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.</p>\n<p>On March 16, Fennec Pharmaceuticals announced a settlement agreement resolving PEDMARK patent litigation.</p>\n<p>Fennec Pharmaceuticals shares gained 1.8% to close at $7.45 on Monday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $18 on Jan. 9, 2026. This analyst has an accuracy rate of 75%.</li>\n<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Neutral rating with a price target of $13 on Aug. 21, 2025. This analyst has an accuracy rate of 66%.</li>\n<li>Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating and boosted the price target from $13 to $14 on Aug. 15, 2025. This analyst has an accuracy rate of 77%.</li>\n</ul>\n<p>Considering buying FENC stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"531\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-1024x531.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/23163903/image-498.png 1240w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51420308/fennec-pharmaceuticals-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call","article_id":"2621868082","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621868082","pubTimestamp":1774298428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FENC":"Fennec Pharmaceuticals Inc."},"translate_title":"Fennec制药公司的盈利即将到来；这些最准确的分析师在收益看涨期权之前修改了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FENC":1},"content_text":"Fennec Pharmaceuticals Inc. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.\nAnalysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core & Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.\nOn March 16, Fennec Pharmaceuticals announced a settlement agreement resolving PEDMARK patent litigation.\nFennec Pharmaceuticals shares gained 1.8% to close at $7.45 on Monday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nPiper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $18 on Jan. 9, 2026. This analyst has an accuracy rate of 75%.\nHC Wainwright & Co. analyst Raghuram Selvaraju maintained a Neutral rating with a price target of $13 on Aug. 21, 2025. This analyst has an accuracy rate of 66%.\nCraig-Hallum analyst Chase Knickerbocker maintained a Buy rating and boosted the price target from $13 to $14 on Aug. 15, 2025. This analyst has an accuracy rate of 77%.\n\nConsidering buying FENC stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}